Association between human leukocyte antigen gene polymorphisms and multiple EPIYA-C repeats in gastrointestinal disorders

Table 2 Comparison of human leukocyte antigen alleles predisposing susceptibility and resistance to gastric cancer/duodenal ulcer in patient and control groups, n (%)

HLA alleles	Patient groupGC + DU, H. pylori (+) (n = 94, alleles = 198)	Control groupNUD + Asymptomatic, H. pylori (+) (n = 86, alleles = 172)	OR	95%CI		P value
				Minimum	Maximum
HLAs increasing susceptibility to GC/DU
HLA-A*02	52 (27.6)	38 (22)	1.34	0.833	2.182	0.2239
HLA-B*35	40 (21.3)	26 (15.1)	1.51	0.880	2.615	0.1329
HLA-DRB1*13	36 (19)	24 (14)	1.46	0.831	2.567	0.1880
HLA-DQA1*01	76 (40)	30 (17.4)	3.21	1.968	5.242	0.0001
HLA-DQB1*06	52 (27.6)	20 (11.6)	2.90	1.652	5.139	0.0002
HLAs making resistant to GC/DU
HLA-A*03	14 (7.4)	20 (11.6)	0.61	0.298	1.252	0.1787
HLA-B*50	0 (0)	10 (5.8)	0.08	0.010	0.680	0.0201
HLA-DRB1*04	16 (8.5)	24 (14)	0.57	0.293	1.120	0.1038
HLA-DQA1*05	28 (14.9)	54 (31.4)	0.38	0.228	0.639	0.0003
HLA-DQB1*03	42 (23)	64 (37.2)	0.48	0.305	0.770	0.0022

HLA: Human leukocyte antigen; H. pylori: Helicobacter pylori; GC: Gastric cancer; DU: Duodenal ulcer; NUD: Non-ulcer dyspepsia; CI: Confidence interval; OR: Odds ratio.